Taysha gene therapies to participate in jmp securities hematology and oncology summit

Dallas, nov. 29, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it will participate in the jmp securities hematology and oncology summit, which is taking place virtually from tuesday, december 6, 2022, through wednesday, december 7, 2022. taysha's president, founder and chief executive officer, ra session ii, will participate in a fire side chat with silvan turkan, ph.d., senior research analyst at jmp securities, at 3:40 pm et on wednesday, december 7, 2022.
TSHA Ratings Summary
TSHA Quant Ranking